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CASE REPORT
Fluoxetine-related ecchymosis treated with venlafaxine: a case report
Hakan Karaşa and Taner Yılmazb
aDepartment of Psychology, Beykent University, Istanbul, Turkey; bDepartment of Guidance and Psychological Counseling, Middle East
Technical University Northern Cyprus Campus, Kalkanlı, Northern Cyprus
ABSTRACT
Selective serotonin reuptake inhibitors (SSRIs) are known to have a relatively favourable side
effect profile. In recent years, there has been an emphasis on the risk of upper
gastrointestinal bleeding in patients taking SSRI antidepressants. Although they may have
some effects on coagulation profile, ecchymosis is a rare clinical manifestation of these
effects. Here, we report a 25-year-old female patient who was diagnosed with major
depressive disorder and manifested spontaneous ecchymoses on her legs rapidly following
fluoxetine use. Her complete blood cell count, prothrombin time, partial thromboplastin
time, bleeding time, and other hematological screening tests were within normal limits. After
discontinuation of fluoxetine, her ecchymoses were resolved in two weeks. Ecchymosis did
not recur after fluoxetine was discontinued, and the patient was switched to venlafaxine.
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Selective serotonin reuptake inhibitors (SSRIs), which
are not superior to tricyclic antidepressants in terms
of efficacy, are commonly used for the treatment of
depression, anxiety disorders, and several other psy-
chiatric disorders thanks to their favourable safety pro-
files [1]. Although SSRIs are relatively safe, they are
known to be associated with several hematological
side effects including bleeding. There are a growing
number of studies reporting an increased risk of bleed-
ing with the use of these agents [2]. In addition, similar
to the other SSRIs, fluoxetine also rarely causes ecchy-
mosis and the literature mostly includes case reports of
this side effect [3,4]. Here, we report a case of
depression who developed ecchymosis after the
initiation of fluoxetine and was successfully treated
with venlafaxine.
Case presentation
A 25-year-old female patient was referred to psychiatry
outpatient clinic with complaints of fatigue, asthenia,
difficulty in concentration, and loss of motivation for
the past three months. The patient scored 26 points
on the Hamilton Rating Scale for Depression. She
was diagnosed with major depressive disorder based
on the Diagnostic and Statistical Manual of Mental
Disorders, Fifth Edition diagnostic criteria. The patient
had no history of alcohol or substance abuse, and had
no concomitant psychiatric diagnoses. She had no his-
tory of previous antidepressant treatments and was
initiated on fluoxetine 20 mg/day. Three days after
initiation of treatment, the patient developed bruises
on both legs. Four days after the initiation of treatment,
an ecchymosis of 3 and 5 cm in diameter around the
knee on both legs was noted. The patient did not report
any physical trauma to the ecchymosis sites. She had
no bleeding or a colour change in urine or stool. She
had no pain in the sites of ecchymosis. Her medical his-
tory revealed no drug use, food allergies, autoimmune
or medical conditions which might have caused the
lesions. Her family history did not reveal any spon-
taneous bleeding disorders or a hematological disorder.
The patient had no lesions on the other parts of her
body and, then, she was referred to hematology outpa-
tient clinic for consultation. Her physical examination
performed by the hematologist did not indicate ecchy-
mosis on any other part of her body. Examinations and
assays did not suggest any hematological pathology. In
addition, laboratory investigations did not suggest any
abnormality. Laboratory test results were as follows:
hemoglobin: 14.3 g/dL; white blood count: 3:54 10E3/
mm3; platelets: 199.400/mm3; mean platelet volume:
7:41; fluorine sedimentation: 12 mm/h; urea: 33 mg/
dL; creatinine: 0.73 mg/dL; sodium: 140 mmoL/L;
potassium: 4.6 mmoL/L; aspartate aminotransferase:
18 IU/L; alanine aminotransferase: 18/L; free T3:
3:19 pg/mL; free T4: 1:42 ng/mL; thyroid stimulating
hormone: 1.80 mU/mL; international normalized
ratio: 1:06; activated partial thromboplastin time:
35.7 sec; and partial thromboplastin: 13.1 s. The hema-
tologist reported fluoxetine-induced ecchymosis. Upon
cessation of fluoxetine treatment, ecchymotic lesions
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rapidly disappeared within 1–2 days and did not recur.
Her depressive complaints, however, continued during
this period. After the initiation of venlafaxine 75 mg/
day, depressive complaints resolved within three
weeks. Ecchymosis lesions did not recur after the
initiation of venlafaxine. Venlafaxine treatment was
continued for one year and her depressive complaints
did not repeat; therefore, pharmacological treatment
was discontinued at the end of one year. During fol-
low-up, no hematological side effects were observed.
Additionally, a telephone contact was performed with
the patient two years after the most recent examination
and she reported no ecchymosis or spontaneous bleed-
ing, or she was not diagnosed with any hematological
disorders.
Discussion
The use of SSRIs is known to be associated with
increased bleeding risk. A recent meta-analysis demon-
strated that SSRI use was associated with a 55%
increase in the rate of upper gastrointestinal system
(GIS) bleedings [2]. Although the exact mechanism
through which SSRIs cause upper GIS bleeding is
unknown, it has been suggested that they increase
bleeding risk by inhibiting serotonin reuptake in the
platelets or by increasing gastric acid secretion [5–7].
Moreover, preclinical studies have shown that platelets
do not synthesize serotonin; therefore, it has been
argued that SSRIs impair platelet functions by reducing
serotonin levels in the platelets [2,6]. Inhibition of
reuptake results in a decline in the level of serotonin
in these cells, which plays a crucial role in platelet
aggregation. In addition, SSRIs induce a decline in
the release of dense granules further impairing the for-
mation of platelet plugs, leading to reduced platelet
aggregation and an increased propensity to bleeding
[8]. The effects of SSRIs and the other antidepressants
on platelet functions may vary. In a study investigating
in vitro effects of serotonin-norepinephrine reuptake
inhibitors (SNRIs) on platelet adhesion and coagu-
lation, sertraline, citalopram, and reboxetine were
shown to decrease platelet adhesion, while no effect
of venlafaxine was demonstrated on this function [6].
Based on these data in the current literature, we
switched our patient to venlafaxine, which is an SNRI
agent believed to be more advantageous in terms of
hematological side effect profile.
Although there is evidence of an increased bleeding
risk, SSRIs are rarely associated with ecchymosis as a
side effect. Previous case reports described develop-
ment of side effects including ecchymosis and purpura
related with the use of paroxetine and sertraline [9,10].
Nevertheless, most of the ecchymosis cases during the
use of SSRIs, as reported in the literature, were indeed
related with the use of fluoxetine [3,4,11]. Our case had
normal platelet count and her activated partial
thromboplastin time and bleeding times were within
normal ranges, suggesting that fluoxetine acts by
impairing platelet aggregation or inhibiting serotonin
reuptake in the platelets without affecting platelet
count or blood clotting factors [7]. Our case developed
ecchymosis due to the use of fluoxetine and sub-
sequently she was switched to venlafaxine, which is
associated with a relatively lower risk of bleeding, com-
pared to SSRIs. To the best of our knowledge, only one
case of ecchymosis associated with venlafaxine treat-
ment was previously reported in the literature [12].
After we switched our case to venlafaxine, ecchymosis
did not recur.
Fluoxetine is a specific and potent neuronal
reuptake inhibitor and it is often associated with a
lower possibility of side effects, as it does not inhibit
noradrenaline or dopamine reuptake [13]. Besides,
fluoxetine is preferred for treatment of several psychia-
tric disorders as a safe agent, since its effects on the
muscarinic, histaminergic, adrenergic, and serotoner-
gic receptors are relatively less extensive, compared to
tricyclic antidepressants. Other than nausea, irritabil-
ity, and sleep disorders, fluoxetine was associated
with a lower rate of side effects, compared to other
SSRIs [14]. On the other hand, compared to other
SSRIs, a higher number of case reports describing
fluoxetine-related ecchymosis can be found in the lit-
erature [3,4]. The fact that our case rapidly developed
ecchymosis on the third day after the initiation of
fluoxetine treatment suggests that there is a casual
relationship between fluoxetine and ecchymosis. Such
a possible relationship is further supported by the
absence of a spontaneous bleeding incident in the
medical history of the patient and the rapid resolution
of ecchymosis within days after the cessation of fluox-
etine. Besides, the fact that our case did not experience
any bleeding event during a period of three years after
fluoxetine use indicates that fluoxetine itself directly
caused ecchymosis, rather than exacerbating a hemato-
logical disorder.
In conclusion, while spontaneous ecchymosis is a
rare side effect of fluoxetine, this possibility should
always be kept in mind for certain patients. In clinical
practice, monitoring skin lesions can be helpful to
avoid advanced hematological complications in
patients who are prescribed fluoxetine. A particular
care must be given while initiating fluoxetine treatment
in patients with history of a hematological disease or in
individuals who have bleeding risk. The possibility of
such untoward hematological side effects can be
reduced preferring SNRIs over SSRIs in patients who
are under the risk of ecchymosis, such as in the case
described.
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